Equity is one of the most powerful and most misinterpreted levers in a healthcare practice sale. On the surface, “equity” can look like a uniform concept. In practice, it can mean very different things depending on the model and the buyer behind it.

Before we get into the mechanics, it helps to understand who this story is about.

Dr. A (the younger partner, age 50) and Dr. F (the senior partner, age 62) were equal owners in a high-performing practice, splitting production 50/50. They had built a durable business with strong economics—approximately $5.4M in revenue and $1.2M in EBITDA—and a team structure that depended heavily on both doctors and their spouses. Both spouses were working in the business and were ready to step away from day-to-day operations.

Dr. F wanted to begin transitioning out over the next five years. Dr. A wanted to preserve momentum, protect the practice’s culture, and participate in the upside of what they had built. What they needed was not just a sale—it was a structure that could deliver liquidity now and create a realistic “second bite of the apple” later.

That’s where equity becomes a real wealth lever.

Understanding Equity in Healthcare Practice Sales

In a practice sale, “equity” can mean fundamentally different structures:

• Minority rollover equity or Hold-Co Equity at the parent/platform level, which may or may not have a clear, near-term liquidity path.
• Joint-venture (JV) equity tied to a defined asset, typically with more transparent economics and clearer monetization mechanics. In this scenario, you retain ownership of part of your practice.
• Earnout-like structures that are sometimes described as “equity,” but function more like contingent compensation tied to performance hurdles.

On paper, each can sound attractive. In reality, equity is a form of risk. This is where credibility comes from the buyer’s history, specifically, whether they have recapitalized before and whether doctors have actually converted equity into cash.

This case study is a clear example of what happens when owners insist on that standard and structure the transaction accordingly.

The Situation: A Partner Transition that Required Precision

In a two-partner practice, timing is increasingly important. If one partner wants to step back while the other is still building, waiting can introduce clinical capacity risk, operational instability, and valuation risk.

Dr. F was prepared to sign a five-year employment agreement, which materially strengthened the buyer’s underwriting case. It reduced near-term replacement risk and supported performance continuity assumptions, helping the practice command a valuation that reflected its true quality.

At the same time, both spouses wanted out of day-to-day operations. That meant any buyer needed the infrastructure to absorb administrative responsibilities without disrupting the practice’s performance.

The Objective: Liquidity Today With An Intentional Second Bite Later

Dr. A and Dr. F were not simply optimizing for the highest headline multiple. Their objective was more nuanced:

• Generate meaningful cash at close
• Retain meaningful equity participation
• Ensure there was a credible mechanism for equity liquidity
• Support a multi-year partner transition while removing spouses from day-to-day roles

TUSK’s Approach: Create Leverage, Then Underwrite The Buyer—Not Just The Offer

We ran a competitive market process and generated multiple offers. As the field narrowed, three finalists emerged.

Two were credible on price and presentation, but lacked a proven record of recapitalizations where doctors had successfully monetized equity. The third had a demonstrated recap engine and a history that made the equity component real.

The Deal Structure: 60% Cash At Close + 40% JV Equity

Dr. A and Dr. F chose the partner with a proven recap track record and closed with a structure that balanced immediate liquidity and future upside.

The Second Bite: Equity Liquidity in 3 Months

The transaction closed at the end of October. Three months later, they were able to monetize on their equity.

The platform executed a recapitalization event—essentially a financing and ownership event at the DSO level that brought in new institutional capital and reset valuation at the platform. For equity holders at the JV level, this created a defined liquidity window: the ability to sell a portion of their equity into the recap event and lock in gains while still retaining meaningful exposure to future value creation.

Dr. A and Dr. F elected to monetize a portion of their equity at that moment because the recap gave them an opportunity to de-risk while still staying invested.

What they did at the recap (3 months post-close):

• Sold 20% of their JV equity
• Generated an additional $2.6M in proceeds
• Retained the remaining equity position, preserving upside for the next value inflection point

The Longer Arc: Repeat Liquidity Events Aligned with the Transition Timeline

The most strategic part of this deal was not the recap in month three—it was what came after.

Once the spouses stepped away from day-to-day roles, operational responsibilities that had historically been “held together” inside the practice were absorbed and institutionalized under the platform.

Meanwhile, clinically, Dr. F’s five-year employment runway did exactly what we expected: it protected continuity for patients and the team, allowed an intentional ramp-down, and preserved buyer confidence in performance stability.

The practice continued to grow at a steady pace, and the doctors continued earning their wages while their equity position appreciated through the platform’s value creation.

Then the platform recapped again.

At each recap event, Dr. A and Dr. F had a choice: hold all equity for a future exit, or strategically monetize portions of it while keeping meaningful exposure.

Liquidity events over time:

• Year 4 recap: the platform recapped again; they sold an additional 5% of their equity, creating another liquidity event while keeping the majority of their equity position intact
• Year 7 recap: the platform recapped again; Dr. F used this window to complete his long-planned transition by selling the remainder of his equity to Dr. A and exiting the business entirely

This is where the structure became more than “economics.” It became a framework for a clean, partner-aligned transition: Dr. F exited predictably, on his timeline, and Dr. A retained both continuity and upside without forcing a premature sale of the entire equity stake.

Outcome: $15.6M lifetime transaction value and $4M+ of incremental equity value

This transaction delivered what both partners needed: immediate liquidity, operational relief, a clear transition runway, and—most importantly—a series of monetization opportunities that validated the equity strategy.

By the end of the arc, the total lifetime economics of the deal reached $15.6M. And the equity component returned more than $4M in additional value beyond the initial sale proceeds.

That incremental value was the result of selecting a buyer with a proven recap engine and negotiating a structure that allowed equity to be monetized in real time, not just at some distant future exit.

Outcome highlights:

• $15.6M total lifetime transaction value
• $4M+ in incremental value created through equity liquidity events
• Spouses exited operational roles, reducing household burden and key-person dependency
• Dr. F transitioned out on a deliberate timeline, preserving continuity and valuation integrity
• Dr. A retained ownership participation and benefited from multiple liquidity windows while continuing to lead growth